Literature DB >> 2757881

The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration.

J van Harten1, J Burggraaf, M Danhof, P van Brummelen, D D Breimer.   

Abstract

1. The pharmacokinetics of nisoldipine (10 mg) was assessed in 10 healthy subjects after single dose and multiple dose oral administration. Apparent liver blood flow was measured, using ICG before and during the absorption phase of nisoldipine. 2. Apparent liver blood flow was increased both on acute and short-term administration of nisoldipine, basal flow being lower on multiple dosing than on acute administration (P less than 0.02). 3. A positive relationship was found between the increase in apparent liver blood flow during absorption of nisoldipine and the flow-dependent part of the total AUC of nisoldipine. 4. The findings of this study indicate that a variable liver blood flow response during the absorption phase of nisoldipine contributes to the pharmacokinetic variability of the drug, both on acute and multiple dose administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757881      PMCID: PMC1379923          DOI: 10.1111/j.1365-2125.1989.tb03420.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

Review 2.  Liver blood flow. II. Effects of drugs and hormones on liver blood flow.

Authors:  P D Richardson; P G Withrington
Journal:  Gastroenterology       Date:  1981-08       Impact factor: 22.682

Review 3.  Conceptual review of the hepatic vascular bed.

Authors:  W W Lautt; C V Greenway
Journal:  Hepatology       Date:  1987 Sep-Oct       Impact factor: 17.425

4.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.

Authors:  C H Kleinbloesem; P van Brummelen; H Faber; M Danhof; N P Vermeulen; D D Breimer
Journal:  Biochem Pharmacol       Date:  1984-11-15       Impact factor: 5.858

5.  The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow.

Authors:  P A Meredith; F Pasanisi; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

6.  Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.

Authors:  L A Bauer; M Stenwall; J R Horn; R Davis; K Opheim; L Greene
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

7.  Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects.

Authors:  J Feely
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

Review 8.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

Authors:  F P Guengerich; M V Martin; P H Beaune; P Kremers; T Wolff; D J Waxman
Journal:  J Biol Chem       Date:  1986-04-15       Impact factor: 5.157

10.  Improvement in exercise performance with nisoldipine, a new second-generation calcium blocker, in stable angina patients.

Authors:  L M Lopez; M R Rubin; J P Holland; J L Mehta
Journal:  Am Heart J       Date:  1985-11       Impact factor: 4.749

View more
  8 in total

1.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

3.  Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure.

Authors:  P H Dunselman; B Edgar; A H Scaf; C E Kuntze; H Wesseling
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

4.  Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians.

Authors:  A Sowunmi; T J Rashid; O O Akinyinka; A G Renwick
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

5.  Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects.

Authors:  P A Soons; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

6.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  The influence of nifedipine and captopril on liver blood flow in healthy subjects.

Authors:  J Burggraaf; R C Schoemaker; J M Kroon; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of nisoldipine coat-core.

Authors:  R Heinig
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 5.577

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.